The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Offer details
Expected size of offer (M): 10m
Expected first date of trading: 08/05/2014
Market: AIM
Location of address at which admission document will be available: Copies of this document will be available free of charge to the public at the registered office of the Company's solicitors, Simmons & Simmons LLP, at CityPoint, One Ropemaker Street, London EC2Y 9SS during normal business hours on any weekday (Saturdays, Sundays and public holidays excepted) until the date falling one month after the date of Admission. Additionally, an electronic version of this document will be available on the Group's website www.rexbionics.com The Admission Document contains full details about the applicant and the admission of its securities.
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Oriel Securities Limited
Nominated Broker (AIM Companies): Oriel Securities Limited

Company details
Name Role
David Macfarlane Non-Executive Chairman
Jeremy Curnock Cook Chief Executive Officer
Peter Worrall Chief Financial Officer
William (Bill) Hunter Non-Executive Director

Facts and Figures
Fiscal year end: 31 March
Incorporated in: England and Wales
Website URL: www.rexbionics.com (as at admission)
space
Description of business:
UMT is currently an investing company with a policy of buying and commercialising technologies in the medical technology area. It has conditionally acquired the entire issued share capital of Rex Bionics Limited ("RBL"), a New Zealand based developer and manufacturer of hands free robotic exoskeletons for use by wheelchair users (the "Acquisition"). Consideration for the Acquisition will be shar...

Person(s) interested:
Shares Held pre Admission % Shares Held pre Admission Shares Held on Admission following Acquisition and loan note conversion * % interest on Admission (including Placing)* BIOSCIENCE MANAGERS PTY LIMITED 12,500 3.68% 12,500 0.09% INTERNATIONAL BIOSCIENCE MANAGERS 12,500 3.68% 12,500 0.09% JEREMY L CURNOCK COOK 12,500 3.68% 26,389 0.20% CHRISTOPHER STAINFORTH 12,500 3.68 12,500 0.09% ROBERT IGGULDEN 12,500 3.68% 12,500 0.09% DR WILLIAM HUNTER 31,600 9.31% 59,377 0.42% PERSHING NOMINEES LIMITED 50,000 14.73% 50,000 0.35% JIM NOMINEES LIMITED 30,603 9.01% 31,353 0.22% XCAP NOMINEES LIMITED 21,000 6.18% 20,250 0.14% HAREWOOD NOMINEES LIMITED 20,681 6.09% 20,681 0.14% LYNCHWOOD NOMINEES LIMITED 12,500 3.68% 12,500 0.09% HUNTER HALL 0 0.0% 1,833,333 12.83% FIDELITY MANAGEMENT & RESEARCH 0 0.0% 1,428,936 10.0% RICHARD LITTLE 0 0.0% 724,259 5.07% NO 8 VENTURES 0 0.0% 2,276,709 15.93% ROBERT IRVING 0 0.0% 714,262 5.00% PAUL MATTHEWS 0 0.0% 1,772,504 12.40% ONE FUNDS MANAGEMENT AS TRUSTEE OF THE ASIA PACIFIC HEALTHCARE FUND II 0 0.0% 1,657,743 11.60%


Union Medtech plc to be renamed Rex Bionics Plc on Admission

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds